熊去氧胆酸治疗诱导的GLOBE评分变化与原发性胆汁性胆管炎患者无肝移植生存相关
在Global PBC队列中纳入3775例接受熊去氧胆酸(UDCA)治疗的原发性胆汁性胆管炎(PBC)患者,中位随访7.2年,730例达到肝移植或死亡复合终点。Cox回归显示,治疗第一年及第二年的GLOBE评分变化均与肝移植或死亡风险独立相关。
要点
- UDCA治疗第一年GLOBE评分变化与肝移植或死亡相关,校正后HR 2.28。
- UDCA治疗第二年GLOBE评分变化亦与肝移植或死亡相关,校正后HR 2.19。
- 基线GLOBE评分与第一年评分变化的交互作用无统计学意义(P=0.296)。
核心结论
- UDCA诱导的GLOBE评分变化与PBC患者无肝移植生存显著相关。
- 肝移植或死亡的相对风险降低稳定,但绝对风险降低高度取决于患者的基线预后。
研究设计与样本
- 研究为Global PBC队列中接受UDCA治疗患者的分析,共纳入3775例。
- 采用Cox回归分析评估GLOBE评分变化与肝移植或死亡风险的关联。
主要发现
- 中位随访7.2年(IQR 3.7-11.5)期间,730例患者达到肝移植或死亡复合终点。
- 第一年GLOBE评分变化中位数为-0.27(IQR -0.56至0.02)。
- 校正治疗前GLOBE评分及第一年评分变化后,第一年GLOBE评分变化与肝移植或死亡相关(校正HR 2.28,95%CI 1.81-2.87,P<0.001)。
- 基线GLOBE评分与第一年GLOBE评分变化的交互作用无统计学意义(P=0.296)。
- 校正基线GLOBE评分及第一年评分变化后,第二年GLOBE评分变化与肝移植或死亡相关(校正HR 2.19,95%CI 1.67-2.86,P<0.001)。
关键数值与推荐
- GLOBE评分变化0-1定义为UDCA治疗第一年内的变化。
- GLOBE评分变化1-2定义为UDCA治疗第二年内的变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Treatment of primary biliary cholangitis (PBC) can improve the GLOBE score. We aimed to assess the association between changes in the GLOBE score (ΔGLOBE) and liver transplantation (LT)-free survival in patients with PBC who were treated with ursodeoxycholic acid (UDCA). METHODS: Among UDCA-treated patients within the Global PBC cohort, the association between ΔGLOBE (ΔGLOBE 0-1 : during the first year of UDCA, ΔGLOBE 1-2 : during the second year) and the risk of LT or death was assessed through Cox regression analyses. RESULTS: Overall, 3,775 UDCA-treated patients were included; 3,424 (90.7%) were female, the median age was 54.0 (interquartile range [IQR] 45.9-62.4) years, and the median baseline GLOBE score was 0.25 (IQR -0.47 to 0.96). During a median follow-up of 7.2 (IQR 3.7-11.5) years, 730 patients reached the combined end point of LT or death. The median ΔGLOBE 0-1 was -0.27 (IQR -0.56 to 0.02). Cox regression analyses, adjusted for pretreatment GLOBE score and ΔGLOBE 0-12 , showed that ΔGLOBE was associated with LT or death (adjusted hazard ratio 2.28, 95% confidence interval 1.81-2.87, P < 0.001). The interaction between baseline GLOBE score and ΔGLOBE 0-1 was not statistically significant ( P = 0.296). The ΔGLOBE 1-2 was associated with LT or death (adjusted hazard ratio 2.19, 95% confidence interval 1.67-2.86, P < 0.001), independently from the baseline GLOBE score and the change in GLOBE score during the first year of UDCA. DISCUSSION: UDCA-induced changes in the GLOBE score were significantly associated with LT-free survival in patients with PBC. While the relative risk reduction of LT or death was stable, the absolute risk reduction was heavily dependent on the baseline prognosis of the patient.
引用
- de Veer RC, van Hooff MC, Corpechot C, et al. Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis. Am J Gastroenterol. 2022. PMID: 36621963. doi:10.14309/ajg.0000000000002128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。